ConductScience.org, home

Trial · NCT01307267

Adverse events5,497

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 0.006mg/kg040
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 0.03mg/kg030
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 0.06mg/kg060
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 0.12mg/kg040
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 0.18mg/kg131
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 0.24mg/kg4426
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 0.3mg/kg030
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 0.6mg/kg040
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 1.2mg/kg5315
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 2.4mg/kg050
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 5mg/kg262
otherAnaemiaBlood and lymphatic system disordersPortion A: PF-05082566 10mg/kg2112
otherAnaemiaBlood and lymphatic system disordersPortion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2030
otherAnaemiaBlood and lymphatic system disordersPortion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2030
otherAnaemiaBlood and lymphatic system disordersPortion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2040
otherAnaemiaBlood and lymphatic system disordersPortion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2030
otherAnaemiaBlood and lymphatic system disordersPortion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2030
otherAnaemiaBlood and lymphatic system disordersPortion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2030
otherAnaemiaBlood and lymphatic system disordersPortion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2040
otherAnaemiaBlood and lymphatic system disordersPortion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^22322

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01307267/events